A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Symbicort Turbuhaler (Budesonide/formoterol)

2 x 160/4.5 microgram, inhalation, bid, 52 weeks

DRUG

Drug: any available COPD treatment; investigator to decide

According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision

Trial Locations (17)

Unknown

Research Site, Nagoya

Research Site, Toyota

Research Site, Yanagawa

Research Site, Hiroshima

Research Site, Asahikawa

Research Site, Sapporo

Research Site, Itami

Research Site, Hitachi

Research Site, Tsukuba

Research Site, Sakaidechō

Research Site, Fujisawa

Research Site, Yokohama

Research Site, Kōshi

Research Site, Kyoto

Research Site, Murata

Research Site, Chūō

Research Site, Setagaya City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY